{
    "clinical_study": {
        "@rank": "80637", 
        "acronym": "EndoPat", 
        "arm_group": [
            {
                "arm_group_label": "Patients with type 2 diabetes", 
                "arm_group_type": "Experimental", 
                "description": "20 individuals with type 2 diabetes"
            }, 
            {
                "arm_group_label": "Healthy subjects", 
                "arm_group_type": "Active Comparator", 
                "description": "20 healthy men and women with no metabolic syndrome"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the effect of hyperinsulinemia and postprandial changes\n      in plasma glucose and lipids concentrations on the endothelial function together with other\n      metabolic parameters in patients with type 2 diabetes (T2D) and in healthy subjects.\n\n      Hypothesis:\n\n      Different changes in endothelial function to acute in vivo induced hyperinsulinemia and\n      after the meal test will be found in patients with T2D compared to healthy subjects.\n\n      A significant relationships between insulin sensitivity, selected adipokines\n      intramyocellular fat content, hepatic fat content and high energy phosphates in soleus\n      muscle will be documented in both groups."
        }, 
        "brief_title": "Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Insulin Resistance", 
            "Type 2 Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Insulin Resistance"
            ]
        }, 
        "detailed_description": {
            "textblock": "20 patients with T2D and 20 healthy control subjects will be examined on an outpatient\n      basis. The following examination will be carried out in each subject after 12 hrs fasting:\n\n        -  Hyperinsulinaemic euglycemic clamp study lasting 4 hours combined with indirect\n           calorimetry and biopsy of subcutaneous adipose tissue and muscle aspiration biopsy\n\n        -  Meal test:Plasma glucose, immunoreactive insulin, plasma lipids, oxidative stress\n           markers and gastrointestinal peptides measured in response to a standard meal(at times\n           0\u00b4,30\u00b4,60\u00b4,120\u00b4,180\u00b4)\n\n        -  At the beginning and after 120 minutes during the meal test and clamp peripheral\n           microvascular endothelial function will be measured using EndoPat(Itamar Medical)\n\n        -  Proton and phosphorus magnetic resonance spectroscopy(MRS).\n\n        -  Dual Energy X-ray Absorptiometry(DXA) scanning to measure body composition."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with T2D:\n\n        Inclusion criteria -\n\n          1. Men and women aged 30-65 years\n\n          2. Body Mass Index in the range of 25 - 45(kg/m2)\n\n          3. Type 2 diabetes mellitus for at least one year\n\n          4. Treatment of T2D: diet or oral antidiabetic agents (stable drug therapy at least 3\n             months before the trial\n\n          5. The presence of metabolic syndrome - any three of the following symptoms:\n\n               1. Abdominal obesity - waist circumference in men >102 cm, in women >88 cm\n\n               2. Diagnosis and treatment of type 2 diabetes\n\n               3. Raised blood pressure (BP): systolic BP > 130 mm Hg or diastolic BP >85 mm Hg,\n                  or treatment of previously diagnosed hypertension\n\n               4. Reduced HDL cholesterol in men < 1 mmol/l, in women  < 1,3 mmol/l   (or\n                  treatment)\n\n               5. Raised triglycerides > 1,7 mmol/l (or treatment)\n\n        4. HbA1c  \u2265 42 a \u2264100 mmol/mol\n\n        Exclusion criteria -\n\n          1. Type 1 diabetes mellitus\n\n          2. Unstable drug therapy at least 3 month before the trial\n\n          3. Pregnancy, breast feeding or trying to become pregnant\n\n          4. Alcoholism or drug use\n\n          5. Presence of other medical condition, which occurs during physical examination,\n             laboratory tests, including pulmonary, neurological or inflammatory disease, which\n             would be considered by the examiner to distort the consistency of data\n\n        Healthy subjects:\n\n        Inclusion criteria -\n\n          1. Men and women aged 30-65 years\n\n          2. Body Mass Index 25-45 (kg/m2)\n\n          3. Absence of metabolic syndrome - not more than any two of the following symptoms:\n\n               1. Abdominal obesity - waist circumference in men >102 cm, in women >88 cm\n\n               2. Diagnosis and treatment of type 2 diabetes or raised fasting plasma glucose\n                  level (FPG >5,6 mmol/l)\n\n               3. Raised blood pressure (BP): systolic BP >130 mm Hg or diastolic BP >85 mm Hg, or\n                  treatment of previously diagnosed hypertension\n\n               4. Reduced HDL cholesterol in men <1 mmol/l, in women <1,3 mmol/l(or treatment)\n\n               5. Raised triglycerides > 1,7 mmol/l (or treatment)\n\n        Exclusion criteria -\n\n          1. Diabetes or impaired glucose tolerance (HbA1c \u226540 mmol/mol and/or FPG >5,6 mmol/l),\n             diagnosed  diabetes in first-line relatives\n\n          2. Pregnancy, breast feeding or trying to become pregnant\n\n          3. Alcoholism or drug use\n\n          4. Presence of other medical condition, which occurs during physical examination,\n             laboratory  tests, including pulmonary, neurological or inflammatory disease, which\n             would be considered by the examiner to distort the consistency of data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946347", 
            "org_study_id": "G981"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Patients with type 2 diabetes", 
                    "Healthy subjects"
                ], 
                "description": "Baguette Cheese Gourmet (Crocodile:\n180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.", 
                "intervention_name": "mixed meal", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Patients with type 2 diabetes", 
                    "Healthy subjects"
                ], 
                "description": "Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long", 
                "intervention_name": "Acute in vivo induced hyperinsulinemia", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Insulin Resistance", 
            "Hyperglycemia", 
            "Endothelial function", 
            "Oxidative stress"
        ], 
        "lastchanged_date": "September 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Prague", 
                    "country": "Czech Republic", 
                    "zip": "140 21"
                }, 
                "name": "Diabetes Center, Institute of Clinical and Experimental Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Hyperinsulinemia and Postprandial Metabolic Changes on Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects", 
        "overall_contact": {
            "email": "terezie.pelikanova@medicon.cz", 
            "last_name": "Terezie Pelikanova Pelikanova, Prof, MD", 
            "phone": "+420 261 364 100"
        }, 
        "overall_contact_backup": {
            "email": "lenka.belinova@medicon.cz", 
            "last_name": "Lenka Belinova, MD", 
            "phone": "+420 261 363 164"
        }, 
        "overall_official": {
            "affiliation": "Diabetes Center, Institute of Clinical and Experimental Medicine", 
            "last_name": "Terezie Pelikanova, Prof, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "at 0 and after 120 minutes during the clamp and 120 minutes after meal ingestion", 
            "measure": "Changes of endothelial function (measured by EndoPat)", 
            "safety_issue": "No", 
            "time_frame": "120 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946347"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute for Clinical and Experimental Medicine", 
            "investigator_full_name": "Prof. Terezie Pelikanova", 
            "investigator_title": "Prof.MUDr.Terezie Pelikanova DrSc.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "0, 30, 60, 120, 180 minutes after meal ingestion", 
                "measure": "Changes in gastrointestinal peptides concentrations", 
                "safety_issue": "No", 
                "time_frame": "180 minutes"
            }, 
            {
                "description": "at 0 and after 120 minutes after meal ingestion", 
                "measure": "Changes in oxidative stress markers", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "measure": "Insulin sensitivity measured as glucose disposal during clamp", 
                "safety_issue": "No", 
                "time_frame": "4 hours"
            }
        ], 
        "source": "Institute for Clinical and Experimental Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute for Clinical and Experimental Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}